FR2715937A1 - Virus MSRV1 et MSRV2 associés ensemble à la sclérose en plaques et leurs constituants nucléiques. - Google Patents
Virus MSRV1 et MSRV2 associés ensemble à la sclérose en plaques et leurs constituants nucléiques. Download PDFInfo
- Publication number
- FR2715937A1 FR2715937A1 FR9401532A FR9401532A FR2715937A1 FR 2715937 A1 FR2715937 A1 FR 2715937A1 FR 9401532 A FR9401532 A FR 9401532A FR 9401532 A FR9401532 A FR 9401532A FR 2715937 A1 FR2715937 A1 FR 2715937A1
- Authority
- FR
- France
- Prior art keywords
- virus
- sequence
- seq
- viruses
- sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000006417 multiple sclerosis Diseases 0.000 title claims abstract description 73
- 230000001717 pathogenic effect Effects 0.000 title abstract description 4
- 239000012678 infectious agent Substances 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 claims abstract description 100
- 102100034343 Integrase Human genes 0.000 claims abstract description 51
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims abstract description 51
- 230000000694 effects Effects 0.000 claims abstract description 46
- 230000001177 retroviral effect Effects 0.000 claims abstract description 36
- 230000003612 virological effect Effects 0.000 claims abstract description 27
- 238000004113 cell culture Methods 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 69
- 239000002773 nucleotide Substances 0.000 claims description 42
- 125000003729 nucleotide group Chemical group 0.000 claims description 42
- 239000012634 fragment Substances 0.000 claims description 30
- 239000000523 sample Substances 0.000 claims description 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 22
- 239000000427 antigen Substances 0.000 claims description 18
- 102000036639 antigens Human genes 0.000 claims description 18
- 108091007433 antigens Proteins 0.000 claims description 18
- 230000000295 complement effect Effects 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- 239000003446 ligand Substances 0.000 claims description 8
- 230000000069 prophylactic effect Effects 0.000 claims description 6
- 239000012472 biological sample Substances 0.000 claims description 5
- 101100349149 Schizosaccharomyces pombe (strain 972 / ATCC 24843) nse2 gene Proteins 0.000 claims 1
- 235000015107 ale Nutrition 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 241001430294 unidentified retrovirus Species 0.000 description 56
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 41
- 238000003752 polymerase chain reaction Methods 0.000 description 29
- 108020004414 DNA Proteins 0.000 description 27
- 210000002845 virion Anatomy 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 20
- 239000000463 material Substances 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- 150000007523 nucleic acids Chemical class 0.000 description 18
- 150000001413 amino acids Chemical group 0.000 description 17
- 229930006000 Sucrose Natural products 0.000 description 16
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 108020004707 nucleic acids Proteins 0.000 description 16
- 102000039446 nucleic acids Human genes 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 239000005720 sucrose Substances 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 230000003321 amplification Effects 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 238000003199 nucleic acid amplification method Methods 0.000 description 14
- 239000000872 buffer Substances 0.000 description 13
- 238000010367 cloning Methods 0.000 description 13
- 208000010094 Visna Diseases 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 238000010804 cDNA synthesis Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 108020004635 Complementary DNA Proteins 0.000 description 10
- 238000012408 PCR amplification Methods 0.000 description 10
- 241001494479 Pecora Species 0.000 description 10
- 238000013459 approach Methods 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 10
- 238000012163 sequencing technique Methods 0.000 description 10
- 108020004437 Endogenous Retroviruses Proteins 0.000 description 9
- 210000003719 b-lymphocyte Anatomy 0.000 description 9
- 230000007170 pathology Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000003757 reverse transcription PCR Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- 239000000178 monomer Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000713326 Jaagsiekte sheep retrovirus Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 108091035707 Consensus sequence Proteins 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 241000701489 Cauliflower mosaic virus Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000016911 Deoxyribonucleases Human genes 0.000 description 4
- 108010053770 Deoxyribonucleases Proteins 0.000 description 4
- 241000700721 Hepatitis B virus Species 0.000 description 4
- 208000037262 Hepatitis delta Diseases 0.000 description 4
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 208000002672 hepatitis B Diseases 0.000 description 4
- 208000029570 hepatitis D virus infection Diseases 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 208000016192 Demyelinating disease Diseases 0.000 description 3
- 208000005331 Hepatitis D Diseases 0.000 description 3
- 208000034189 Sclerosis Diseases 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 241000713325 Visna/maedi virus Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 230000005784 autoimmunity Effects 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 3
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 241000713333 Mouse mammary tumor virus Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000002987 choroid plexus Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241001213909 Human endogenous retroviruses Species 0.000 description 1
- 101150027427 ICP4 gene Proteins 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 108010007403 Immediate-Early Proteins Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000713877 Simian sarcoma-associated virus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- -1 acids nucleic acids Chemical class 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 208000010934 demyelinating disease of central nervous system Diseases 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000006872 enzymatic polymerization reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9401532A FR2715937A1 (fr) | 1994-02-04 | 1994-02-04 | Virus MSRV1 et MSRV2 associés ensemble à la sclérose en plaques et leurs constituants nucléiques. |
| ES95420027T ES2233936T3 (es) | 1994-02-04 | 1995-02-06 | Virus msrv1 asociado a la esclerosis en placas, sus constituyentes nucleicos y sus aplicaciones. |
| PCT/FR1995/000142 WO1995021256A1 (fr) | 1994-02-04 | 1995-02-06 | Virus msrv1 et agent pathogene et/ou infectant msrv2 associes a la sclerose en plaques, leurs constituants nucleiques et leurs applications |
| NZ279855A NZ279855A (en) | 1994-02-04 | 1995-02-06 | Msrv1 and msrv2 pathogenic and/or infectious agents associated with ms, nucleic acids encoding them and diagnostic and therapeutic applications |
| FI954699A FI954699A7 (fi) | 1994-02-04 | 1995-02-06 | MSRV1-virus ja multippeliskleroosiin liittyvä patogeeninen ja/tai infe ktoiva MSRV2-agenssi, niiden nukleiinihappokomponentteja ja niiden sov ellutuksia |
| AT95420027T ATE285475T1 (de) | 1994-02-04 | 1995-02-06 | Msrv1 virus der mit multipler sklerose verbunden ist, seine nukleären bestandteile und verwendungen |
| US08/384,137 US5871996A (en) | 1994-02-04 | 1995-02-06 | Retrovirus agents MSRV1 and MSRV2 associated with multiple sclerosis |
| DE0674004T DE674004T1 (de) | 1994-02-04 | 1995-02-06 | MSRV1 Virus und ansteckender und/oder krankheitserregender MSRV2, die mit Multipler Sklerose verbunden sind, ihre nukleären Bestandteile und Verwendungen. |
| AU17114/95A AU704440B2 (en) | 1994-02-04 | 1995-02-06 | MSRV1 virus and MSRV2 pathogenic and/or infectious agent associated with multiple sclerosis, nucleic acid components and applications of same |
| EP95420027A EP0674004B1 (fr) | 1994-02-04 | 1995-02-06 | Virus MSRV1 associé à la Sclérose en Plaques, ses constituants nucléiques et leurs applications |
| JP52042695A JP3611856B2 (ja) | 1994-02-04 | 1995-02-06 | 多発性硬化症に関与するｍｓｒｖ１ウイルスおよびｍｓｒｖ２病因性及び／又は感染性の作因、核酸成分およびその応用 |
| DE69533863T DE69533863T2 (de) | 1994-02-04 | 1995-02-06 | MSRV1 Virus der mit Multipler Sklerose verbunden ist, seine nukleären Bestandteile und Verwendungen |
| CA002141907A CA2141907A1 (fr) | 1994-02-04 | 1995-02-06 | Virus msrv1 et agent pathogene et/ou infectant msrv2 associes a la sclerose en plaques, leurs constituants nucleiques et leurs applications |
| US08/471,969 US5871745A (en) | 1994-02-04 | 1995-06-06 | Multiple sclerosis related virus |
| US08/471,724 US5800980A (en) | 1899-02-04 | 1995-06-06 | Detection of MSRV1 virus and MSRV2 pathogen and/or infective agent associated with multiple sclerosis, by nucleic acid hybridization |
| US08/470,006 US5962217A (en) | 1994-02-04 | 1995-06-06 | MSRV1 virus and MSRV2 pathogen and/or infective agent associated with multiple sclerosis, and biopolymer constituents thereof |
| NO953925A NO953925L (no) | 1994-02-04 | 1995-10-03 | MSRV1-virus og MSRV2-patogent og/eller infeksiöst middel forbundet med multippel sklerose, nukleinsyrekomponenter og anvendelse av disse |
| US09/133,411 US6342383B1 (en) | 1994-02-04 | 1998-08-13 | Cell lines and viral isolates associated with multiple sclerosis |
| US09/200,990 US6184025B1 (en) | 1994-02-04 | 1998-11-30 | Viral isolates associated with multiple sclerosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9401532A FR2715937A1 (fr) | 1994-02-04 | 1994-02-04 | Virus MSRV1 et MSRV2 associés ensemble à la sclérose en plaques et leurs constituants nucléiques. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2715937A1 true FR2715937A1 (fr) | 1995-08-11 |
| FR2715937B1 FR2715937B1 (enrdf_load_stackoverflow) | 1997-02-14 |
Family
ID=9459973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9401532A Granted FR2715937A1 (fr) | 1899-02-04 | 1994-02-04 | Virus MSRV1 et MSRV2 associés ensemble à la sclérose en plaques et leurs constituants nucléiques. |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2715937A1 (enrdf_load_stackoverflow) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6555091B1 (en) | 1997-04-29 | 2003-04-29 | Bio Merieux | Polypeptide capable of reacting with antibodies of patients suffering from multiple sclerosis and uses |
| EP1612270A2 (fr) | 1997-07-07 | 2006-01-04 | Biomerieux | Matérial nucléique retroviral et fragments nucléotidiques notamment associés à la sclérose en plaques et/ou la polyarthrite rhumatoide, à des fins de diagnostic, prophylactiques et thérapeutiques |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993007259A1 (en) * | 1991-10-11 | 1993-04-15 | Scleroseforeningen (The Danish Ms-Society) | Type c-like human retrovirus linked to multiple sclerosis (ms) |
| WO1993020188A1 (fr) * | 1992-04-03 | 1993-10-14 | Bio Merieux | Procede et milieu de culture pour l'obtention de cellules infectees par un virus associe a la sclerose en plaques |
| WO1993023550A2 (en) * | 1992-05-18 | 1993-11-25 | Genentech, Inc. | Activation of oligomerizing receptors by using fused receptor ligands |
| WO1994028138A1 (en) * | 1993-05-24 | 1994-12-08 | University College London | Multiple sclerosis virus |
-
1994
- 1994-02-04 FR FR9401532A patent/FR2715937A1/fr active Granted
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993007259A1 (en) * | 1991-10-11 | 1993-04-15 | Scleroseforeningen (The Danish Ms-Society) | Type c-like human retrovirus linked to multiple sclerosis (ms) |
| WO1993020188A1 (fr) * | 1992-04-03 | 1993-10-14 | Bio Merieux | Procede et milieu de culture pour l'obtention de cellules infectees par un virus associe a la sclerose en plaques |
| WO1993023550A2 (en) * | 1992-05-18 | 1993-11-25 | Genentech, Inc. | Activation of oligomerizing receptors by using fused receptor ligands |
| WO1994028138A1 (en) * | 1993-05-24 | 1994-12-08 | University College London | Multiple sclerosis virus |
Non-Patent Citations (7)
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6555091B1 (en) | 1997-04-29 | 2003-04-29 | Bio Merieux | Polypeptide capable of reacting with antibodies of patients suffering from multiple sclerosis and uses |
| EP1612270A2 (fr) | 1997-07-07 | 2006-01-04 | Biomerieux | Matérial nucléique retroviral et fragments nucléotidiques notamment associés à la sclérose en plaques et/ou la polyarthrite rhumatoide, à des fins de diagnostic, prophylactiques et thérapeutiques |
| US7771927B1 (en) | 1997-07-07 | 2010-08-10 | Biomerieux | Multiple sclerosis-associated retroviral (MSRV) nucleic acids corresponding to the Env region |
| US8088910B2 (en) | 1997-07-07 | 2012-01-03 | Biomerieux | Isolated multiple sclerosis (MS)-associated retrovirus (MSRV) nucleic acids corresponding to the gag region |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2715937B1 (enrdf_load_stackoverflow) | 1997-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0674004B1 (fr) | Virus MSRV1 associé à la Sclérose en Plaques, ses constituants nucléiques et leurs applications | |
| EP0789077B1 (fr) | Matériel viral et fragments nucléotidiques associés à la sclérose en plaques, à des fins de diagnostic, prophylactiques et thérapeutiques | |
| US7674888B2 (en) | Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes | |
| EP1000158B1 (fr) | Sequences retroviraux endogenes, associees a des maladies auto-immunes et/ou a des perturbations de la grossesse | |
| FR2715937A1 (fr) | Virus MSRV1 et MSRV2 associés ensemble à la sclérose en plaques et leurs constituants nucléiques. | |
| EP0731168A1 (fr) | Virus MSRV-1 et agent pathogène et/ou infectant MSRV-2 associés à la polyarthrite rhumatoide | |
| FR2715939A1 (fr) | Virus MSRV2 associé à la sclérose en plaques, et ses constituants nucléiques. | |
| FR2727428A1 (fr) | Virus msrv1 associe a la sclerose en plaques et ses constituants nucleiques | |
| FR2715938A1 (fr) | Constituants nucléiques du virus MSRV1, associé à la sclérose en plaques. | |
| EP1612270B1 (fr) | Matérial nucléique retroviral et fragments nucléotidiques, associés à la sclérose en plaques, à des fins de diagnostic, prophylactiques et thérapeutiques | |
| FR2728585A1 (fr) | Virus msrv1 et agent pathogene et/ou infectant msrv2 associes a la sclerose en plaques et leurs constituants nucleiques | |
| FR2715936A1 (fr) | Virus MSRV1 associé à la sclérose en plaques, et ses constituants nucléiques. | |
| FR2830019A1 (fr) | Molecules d'acides nucleiques d'hdv, leurs fragments et leurs apllications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |